Table 3.
Severity and QOL scores during sirolimus treatment
| Severity score | QOL score | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All score | Physical score | Psychological score | ||||||||||
| Pretreatment | 6 months | p valuea | Pretreatment | 6 months | p valuea | Pretreatment | 6 months | p valuea | Pretreatment | 6 months | p valuea | |
| All patients (n = 20) | 8.0 (3–20) | 5.0 (1–20) | 0.0029 | 58.1 (17.4–94.6) | 77.3 (7.7–91.3) | 0.0129 | 50.0 (0–100) | 77.6 (0–100) | 0.0105 | 65.0 (12.5–100) | 75.8(16.7–100) | 0.0052 |
| PR patients (n = 10) | 8.0 (3–13) | 4.5 (1–7) | 0.0020 | 58.1 (17.4–84.7) | 76.2 (51.1–91.3) | 0.0117 | 48.4 (18.8–98.4) | 77.6 (21.9–98.4) | 0.0078 | 65.0 (12.5–78.1) | 75.8 (60–90.5) | 0.0156 |
| SD patients (n = 10) | 6.5 (3–20) | 5.5 (1–20) | 0.4375 | 63.3 (23.9–94.6) | 79.8 (7.7–91.3) | 0.3828 | 53.1 (0–100) | 69.5 (0–100) | 0.367 | 67.5 (27.5–-100) | 82.5 (16.7–100) | 0.2188 |
Values presented as median (range)
PR partial response, SD stable disease
aWilcoxon signed rank test for comparison between pretreatment and 6 months